

24 h with progressive dose increments was started simultaneously. The patient currently maintains adequate HbA1c levels. In the most recent blood test, blood glucose was 135 mg/dl, and HbA1c 7%, with a dose increase up to 45 mg daily.

The patient is currently controlled by the diabetes unit of our hospital, with a good clinical course and adequate control of the disease.

One year later, the male sibling was admitted due to a random blood glucose level of 214 mg/dl, glycosuria and HbA1c 8%. Given the background of our patient, and with the suspicion of MODY-3 onset, treatment with sulfonylureas was started. Four days after admission the glycemia values were found to be adequate. The results of the genetic study are pending confirmation.

Since MODY-3 is an unusual form of diabetes in paediatric patients, we consider the publication of this case to be of considerable interest, especially as several members of the same family are affected. We underline the importance of clinical suspicion in establishing a proper diagnosis, since it allowed the treatment to be modified and the disease to be adequately controlled, leading to an improvement in patient quality of life.

Collaboration with the Research Unit of Hospital de Cruces (Bilbao, Spain) proved essential in obtaining a correct diagnosis.

References

1. Tapia L, Córdoba E, Picazo B, Ranchor P. Diabetes MODY. Una causa frecuente de hiperglucemia. *An Pediatr*. 2008;69:565-7.
2. Thunander M, Petersson C, Jonzon K, Fornander J, Ossiansson B, Torn C. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. *Diabetes Res Clin Pract*. 2008;82:247-55.
3. Barrio R. Diabetes mellitus en la edad pediátrica: diabetes tipo 1, diabetes tipo 2 y MODY. *Endocrinol Nutr*. 2004;51: 31-7.
4. Fajans SS, Bell GI. MODY. *Diabetes Care*. 2011;34: 1878-84.
5. Ræder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. *Nat Genet*. 2006;38: 54-62.
6. Martín-Campagne E, Roa-Llamazares C, Ballester-Herrera MJ, Palomo-Atance E, Giralt-Muiña P. Diagnóstico inusualmente precoz de diabetes MODY-3 condicionado por la obesidad. *Rev Esp Endocrinol Pediatr*. 2012;3:72-5.

María José Sánchez Malo^{a,*}, Marta Arrudi Moreno^a, Gracia María Lou Francés^b

^a Servicio de Pediatría, Hospital Universitario Miguel Servet, Zaragoza, Spain

^b Unidad de Diabetes Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain

* Corresponding author.

E-mail address: mjsanchezmalo@gmail.com
(M.J. Sánchez Malo).

2530-0180/

© 2019 SEEN and SED. Published by Elsevier España, S.L.U. All rights reserved.

PARENTERAL NUTRITION: ALBUMIN VERSUS TOTAL PROTEINS IN THE ASSESSMENT OF PLASMA CALCIUM TO ADJUST PARENTERAL NUTRITION: A SERIES OF CASES[☆]



Nutrición parenteral: albúmina versus proteínas totales en la valoración del calcio plasmático para ajustar la nutrición parenteral: a propósito de una serie de casos

Plasma calcium is the parameter most commonly used to determine patient calcium levels in clinical practice. However, in certain physiological conditions, plasma calcium may not reflect the true clinical situation of the patient. Calcemia (blood calcium concentration) is closely regulated in the body, with total calcium values between 2.2 and 2.6 mmol/l (9–10.5 mg/dl) and ionic calcium values between

1.1 and 1.4 mmol/l (4.5–5.6 mg/dl). Forty percent of circulating plasma calcium is bound to proteins (mainly albumin, but also to globulins), 6% is bound to phosphates, citrate and bicarbonate, and the remaining 54% corresponds to ionic calcium.¹ The total calcium values change when the plasma protein levels change, while ionic calcium remains unchanged.^{2,3} Situations where calcemia can be strongly influenced by changes in plasma protein levels include volume overload, malnutrition and nephrotic syndrome. Hypoalbuminemia can also be found in patients with cancer or surgical complications (bleeding, fistula, intestinal perforation, etc.). In these cases, we observe a decrease in total plasma calcium, but not in ionic calcium, a situation known as pseudohypocalcemia.⁴ There are other circumstances in which total calcium is hardly evaluable, such as a reduced glomerular filtration rate and alkalosis, since alterations in acid-base equilibrium cause H⁺ ions to compete with Ca²⁺ for the protein binding points, though total calcium remains unchanged.⁵⁻⁷ However, when there are alterations in acid-base equilibrium, the free calcium fraction is modified, and the patients clinically manifest hypocalcemia due to a decrease in ionic calcium, thereby underlining the importance of determining it through laboratory tests.⁸ Of note is the high frequency of hypoproteinemia in patients subjected to total parenteral nutrition (TPN) (approximately 85%), which points to the need for strict control in such cases. When interpreting the biochemical parameters of a patient,

[☆] Please cite this article as: García L, Fernández M, Bengoa N, Pintor R, Arrieta F. Nutrición parenteral: albúmina versus proteínas totales en la valoración del calcio plasmático para ajustar la nutrición parenteral: a propósito de una serie de casos. *Endocrinol Diabetes Nutr*. 2019;66:272-274.

$$\text{Corrected total calcium (mg/dL)} = \frac{\text{Measured calcium (mg/dL)}}{[(\text{TP (g/dL)})/16] + 0.55}$$

$$\text{Corrected total calcium (mg/dL)} = \text{Measured calcium (mg/dL)} + 0.80 \times [4 - \text{albúmina sérica (g/dL)}]$$

Figure 1 Equations for total calcium correction for total proteins and serum albumin.

Table 1 Plasma calcium levels, total protein levels, serum albumin levels, corrections and ionic calcium corresponding to each of the patients analysed.

Case	Plasma calcium (mg/dl) Reference [8.9–10.3]	TP (g/dl) Reference [6.4–8.3]	Serum albumin (g/dl) Reference [3.5–5.0]	Calcium corrected for TP (mg/dl) Reference [8.9–10.3]	Calcium corrected for serum albumin (mg/dL) Reference [8.9–10.3]	Ionic calcium (mg/dl) Reference [4.2–5.4]
1	7.5	5.1	1.7	8.5	9.34	4.65
2	7.7	6.2	1.6	8.2	9.62	4.5
3	8.1	5.3	2.4	9.1	9.38	4.41
4	7.9	5.4	1.2	8.8	10.14	5.04
5	7.5	3.8	1.2	9.3	9.74	4.67
6	7.1	3.9	1.9	8.7	8.78	4.30
7	8.0	5.1	2.5	9.1	9.2	4.56

TP: total proteins.

uncorrected plasma calcium is of no diagnostic value and must be confirmed by the measurement of ionic calcium as the gold standard. When ionic calcium cannot be determined, the total protein (TP) or albumin correction methods can be used (Fig. 1).^{1,5}

A series of cases are presented below, corresponding to patients receiving TPN and followed-up on by the Nutrition Unit of Hospital Universitario Ramón y Cajal (Madrid, Spain). An analysis is made of the best calcium adjustment method for the diagnosis of hypocalcemia, using equations that correct the plasma calcium levels and afford estimates that are closer to the real concentration.

The indications of TPN were as follows: case 1: a 53-year-old woman operated upon due to a pelvic tumour; case 2: a 54-year-old male with perforation of the sigmoid colon and peritonitis; case 3: a 60-year-old woman with peritoneal pseudomyxoma and peritoneal carcinomatosis; case 4: a 72-year-old male with urothelial carcinoma, chronic calcifying pancreatitis and acute lithiasic cholecystitis; case 5: a 79-year-old woman operated upon due to postsurgery eventration; case 6: a 56-year-old male with esophageal adenocarcinoma; and case 7: a 74-year-old male with a metal mitral valve prosthesis and annuloplasty, pneumonia and respiratory distress syndrome.

Total plasma calcium, TP and albumin were analysed with the ARCHITECT c16000 Abbot system (the routine protocol in the laboratory of our hospital), and TP and albumin correction methods were used. Ionic calcium was determined by potentiometry (GEM Premier 4000 gasometer). In order for hypocalcemia to be symptomatic (Trousseau and Chvostek signs), calcium levels must be <8 mg/dL. The above-mentioned patients had low calcium levels without clinical manifestations, no history of hypocalcemia, and were not receiving drugs capable of inducing hypocalcemia. With correction, plasma calcium was seen to exceed 8 mg/dL. Fifty-seven percent of the patients continued to

show hypocalcemia after calcium correction for proteins, but only 14% showed hypocalcemia after correction for albumin. On contrasting these values with those of ionic calcium, all the calcium values were found to be normal (pseudo-hypocalcemia) (Table 1).

Our study indicates that calcemia correction for albumin is more reliable for correctly diagnosing hypocalcemia.¹⁰ The cases presented reflect the influence of protein/albumin upon the calcium levels, as previously reported in the literature, mainly in patients with renal failure.⁶ This may result in an incorrect diagnosis, which in some cases could lead to the provision of TPN with more calcium than necessary. Routine biochemical testing usually reports total calcium levels and protein-corrected levels, but not albumin-corrected or ionic calcium levels. However, there is still controversy in the literature regarding the best method for measuring plasma calcium, with significant differences in terms of costs and clinical sensitivity.⁸

We conclude that it is essential to accurately determine calcemia in patients receiving TPN as well as in all hospitalized patients in general. It is therefore advisable to request albumin in the laboratory tests and, in the event of doubt, to determine ionic calcium, particularly in patients with alkalosis and/or altered renal function. If albumin or blood gases are not immediately available, the laboratory test results should be examined with caution, especially if the reported calcium concentration is <8 mg/dL. In such a case, the clinical condition of the patient should be prioritised, TPN being supplemented with calcium only in the presence of symptoms of hypocalcemia. However, while the study suggests that calcium correction for albumin is more useful in clinical practice, and specifically for adjusting parenteral nutrition, than correction for proteins, studies involving larger samples are needed to consolidate these findings.

Financial support

The present study has received no specific support from public, commercial or non-profit sources.

References

1. Guillén JA, Hawkins MA, Mislov B, Flores V. Reactantes de fase aguda y su impacto en el estado nutricional. *Revista Médica Científica*. 2001;14:12–8.
2. Baird GS. Ionized calcium. *Clin Chim Acta*. 2011;412:696–701.
3. Pallardo Sánchez LF, Lucas Morante T, Marazuela Azpiroz M, Rovira Loscos A. Endocrinología clínica. Madrid: Ed. Díaz de Santos SA; 2013.
4. Liamis G, Liberopoulos E, Barkas F, Elisaf M. Spurious electrolyte disorders: a diagnostic challenge for clinicians. *Am J Nephrol*. 2013;38:50–7.
5. Muñoz Pérez M, Buño Soto A, Díaz García R, Galán Ortega A, Guevara Ramírez P, Guillén Campuzano E, et al. Recomendaciones para la medida del calcio ionizado. Documentos de la SEQC. 2010;7–11.
6. Kaku Y, Ookawara S, Miyazawa H, Ito K, Ueda Y, Hirai K, et al. Approximation of corrected calcium concentrations in advanced chronic kidney disease patients with or without dialysis therapy. *Nephron Extra*. 2015;5:39–49.
7. Kelly A, Levine MA. Hypocalcemia in the critically ill patient. *J Intensive Care Med*. 2013;28:166–77.
8. Ridefelt P, Helmersson-Karlqvist J. Albumin adjustment of total calcium does not improve the estimation of calcium status. *Scand J Clin Lab Invest*. 2017;77:442–7.
9. Gómez Hoyos E, Fernández-Peña S, Cuesta M, Ortolá A, Matía P, Pérez-Ferre N, et al. Hyponatremia in patients receiving parenteral nutrition: the importance of correcting serum sodium for total proteins. The role of the composition of parenteral nutrition in the development of hyponatremia. *Eur J Clin Nutr*. 2018;72:446–51.
10. Carroll B, Fleisher M, Pessin MS, Richardson S, Ramanathan LV. Pseudohypocalcemia in cancer patients: a recommendation for the postanalytical correction of serum calcium in patients with hypoalbuminemia. *Clin Chem*. 2017;63:1302–4.

Lorena García, María Fernández, Nuria Bengoa,
Rosario Pintor, Francisco Arrieta*

Hospital Universitario Ramón y Cajal, Madrid, Spain

* Corresponding author.

E-mail address: arri68@hotmail.com (F. Arrieta).

2530-0180/

© 2019 SEEN and SED. Published by Elsevier España, S.L.U. All rights reserved.